Journal of Bioequivalence & Bioavailability

In-Vivo studies on the bioequivalence of some brands of Fexofenadine tablets marketed in Punjab

3^rd World Congress Bioavailability & Bioequivalence

March 26-28, 2012 Marriott Hotel & Convention Centre, Hyderabad, India

Aastha Gupta, Navneet Bhulli, Shiwang Sharma, Mr. Arvind Sharma, Dr. Sandeep Arora and Bhumika Sharma

Posters: J Bioequiv Availab

Abstract:

Objective: Fexofenadine is effective in the management of allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy. This study was aimed to assess the bioequivalence of randomly selected brands of fexofenadine tablets in human urine by simple spectrophotometric method marketed in Punjab ,India . Method: Bioavailability assessment was conducted by measuring the concentration of drugs in the urine and bioavailability data was presented as cumulative quantity of drugs recovered in urine in 24 hours. Main: Outcome Measure Cumulative quantity of drugs recovered in urine in 24 hours and estimation of relative bioavailabity. Result: The two different brands of of fexofenadine were significantly bioequivalent. The result of the percentage cumulative quantity of drug recovered from urine showed that there was no statistical significant difference among fexofenadine brands. Conclusion: The various brands of fexofenadine (F1, F2) in punjab exhibited same bioavailability data in vivo and can be said to be bioequivalents. Keywords: Anti-allergic, Bioequivalence, Generic substitution, India